Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Soria, Jean-Charles, Prof, Felip, Enriqueta, MD, Cobo, Manuel, MD, Lu, Shun, MD, Syrigos, Konstantinos, Prof, Lee, Ki Hyeong, MD, Göker, Erdem, MD, Georgoulias, Vassilis, Prof, Li, Wei, MD, Isla, Dolores, MD, Guclu, Salih Z, MD, Morabito, Alessandro, MD, Min, Young J, MD, Ardizzoni, Andrea, MD, Gadgeel, Shirish M, Prof, Wang, Bushi, PhD, Chand, Vikram K, MD, Goss, Glenwood D, Prof
Published in The lancet oncology (01.08.2015)
Published in The lancet oncology (01.08.2015)
Get full text
Journal Article
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
Zhang, Li, Prof, Ma, Shenglin, MD, Song, Xiangqun, MSc, Han, Baohui, MD, Cheng, Ying, MSc, Huang, Cheng, MD, Yang, Shujun, MD, Liu, Xiaoqing, MD, Liu, Yunpeng, MD, Lu, Shun, MD, Wang, Jie, MD, Zhang, Shucai, MD, Zhou, Caicun, MD, Zhang, Xiangwei, MD, Hayashi, Nobuya, BA, Wang, Mengzhao, MD
Published in The lancet oncology (01.05.2012)
Published in The lancet oncology (01.05.2012)
Get full text
Journal Article
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
Drilon, Alexander, Chiu, Chao-Hua, Fan, Yun, Cho, Byoung Chul, Lu, Shun, Ahn, Myung-Ju, Krebs, Matthew G., Liu, Stephen V., John, Thomas, Otterson, Gregory A., Tan, Daniel S.W., Patil, Tejas, Dziadziuszko, Rafal, Massarelli, Erminia, Seto, Takashi, Doebele, Robert C., Pitcher, Bethany, Kurtsikidze, Nino, Heinzmann, Sebastian, Siena, Salvatore
Published in JTO clinical and research reports (01.06.2022)
Published in JTO clinical and research reports (01.06.2022)
Get full text
Journal Article
Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors
Dong, Xiaorong, Li, Xingya, Chen, Jianhua, Ma, Shenglin, Mu, Deguang, Hu, Jie, Lu, Shun
Published in JTO clinical and research reports (01.02.2023)
Published in JTO clinical and research reports (01.02.2023)
Get full text
Journal Article
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
Lu, Shun, Fang, Jian, Li, Xingya, Cao, Lejie, Zhou, Jianying, Guo, Qisen, Liang, Zongan, Cheng, Ying, Jiang, Liyan, Yang, Nong, Han, Zhigang, Shi, Jianhua, Chen, Yuan, Xu, Hua, Zhang, Helong, Chen, Gongyan, Ma, Rui, Sun, Sanyuan, Fan, Yun, Fan, Songhua, Yu, Jie, Lu, Puhan, Luo, Xian, Su, Weiguo
Published in JTO clinical and research reports (01.10.2022)
Published in JTO clinical and research reports (01.10.2022)
Get full text
Journal Article
Prognostic significance of the extent of lymph node involvement in stage II-N1 non-small cell lung cancer
Li, Zi-Ming, Ding, Zheng-Ping, Luo, Qing-Quan, Wu, Chun-Xiao, Liao, Mei-Lin, Zhen, Ying, Chen, Zhi-Wei, Lu, Shun
Published in Chest (01.10.2013)
Published in Chest (01.10.2013)
Get more information
Journal Article
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
Wang, Jie, Wu, Yi-Long, Lu, Shun, Wang, Qun, Li, Shanqing, Zhong, Wen-Zhao, Wang, Qiming, Li, Wei, Wang, Buhai, Chen, Jun, Cheng, Ying, Duan, Hongbing, Li, Gaofeng, Shan, Li, Liu, Yangbo, Liu, Jing, Huang, Xiangning, Bolanos, Ana, He, Jie
Published in JTO clinical and research reports (01.02.2024)
Published in JTO clinical and research reports (01.02.2024)
Get full text
Journal Article
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
Wu, Yi-Long, Lu, Shun, Yang, James Chih-Hsin, Zhou, Jianying, Seto, Takashi, Ahn, Myung-Ju, Su, Wu-Chou, Yamamoto, Noboru, Kim, Dong-Wan, Paolini, Jolanda, Usari, Tiziana, Iadeluca, Laura, Wilner, Keith D., Goto, Koichi
Published in JTO clinical and research reports (01.10.2022)
Published in JTO clinical and research reports (01.10.2022)
Get full text
Journal Article
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC
Zhou, Qing, Soo, Ross A., Chang, Gee-Chen, Chiu, Chao-Hua, Hayashi, Hidetoshi, Kim, Sang-We, Teraoka, Shunsuke, Goto, Yasushi, Zhou, Jianying, Ho-Fun Lee, Victor, Kim, Dong-Wan, Han, Baohui, Chung Man Ho, James, Lin, Chia-Chi, Lu, Shun, Polli, Anna, Calella, Anna Maria, Martini, Jean-François, Wong, Chew Hooi, Mok, Tony, Kim, Hye Ryun, Wu, Yi-Long
Published in JTO clinical and research reports (01.05.2023)
Published in JTO clinical and research reports (01.05.2023)
Get full text
Journal Article
Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial
Yang, James Chih-Hsin, Mok, Tony S.K., Lu, Shun, Nakagawa, Kazuhiko, Yamamoto, Nobuyuki, Shi, Yuan-Kai, Zhang, Li, Soo, Ross A., Morita, Satoshi, Tamura, Tomohide
Published in JTO clinical and research reports (01.03.2021)
Published in JTO clinical and research reports (01.03.2021)
Get full text
Journal Article
Meta-Analysis of First-Line Pemetrexed plus Platinum Treatment in Comparison with Other Platinum Based Doublet Regimens in Elderly East Asian Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
Lu, Shun, MD, Cheng, Ying, MD, Zhou, Cai-cun, MD, Wang, Jie, MD, PhD, Yang, James Chih-Hsin, MD, PhD, Zhang, Ping-hai, MD, Zhang, Xiao-qing, MD, Wang, Xin, PhD, Orlando, Mauro, MD, Wu, Yi-long, MD
Published in Clinical lung cancer (2016)
Published in Clinical lung cancer (2016)
Get full text
Journal Article
Efficacy and Safety of Anti–Programmed Death-Ligand 1 Monoclonal Antibody Socazolimab With Carboplatin and Etoposide for Extensive-Stage SCLC: Results From the Phase 1b Clinical Trial
Lu, Shun, Chen, Zhiwei, Cui, Jiuwei, Guo, Renhua, Li, Ziming, Li, Benjamin Xiaoyi, Dai, Xiangrong
Published in JTO clinical and research reports (01.04.2023)
Published in JTO clinical and research reports (01.04.2023)
Get full text
Journal Article
The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells
Yu, Yong-Feng, MD, Chen, Zhi-Wei, MD, Li, Zi-Ming, MD, Li, Zong-Hai, MD, PhD, Lu, Shun, MD, PhD
Published in Current therapeutic research (01.04.2009)
Published in Current therapeutic research (01.04.2009)
Get full text
Journal Article